|Bid||163.00 x 800|
|Ask||164.98 x 900|
|Day's Range||163.00 - 172.50|
|52 Week Range||96.42 - 174.50|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||172.11|
GW Pharmaceuticals (NASDAQ:GWPH) shares were surging on Wednesday as the U.S. Drug and Enforcement Administration (DEA) has plans to reclassify one of its medications. The company’s shares were on the rise, while trading volume was also soaring by more than four times the company’s daily average following a report from Morgan Stanley’s David Lebowitz. The report claimed that the agency has plans to reclassify the company’s Epidiolex (cannabidiol), which will now be allowed for medicinal use.
Shares of several popular Canadian marijuana producers--including Tilray (TLRY), Canopy Growth (CGC), and Cronos Group (CRON)--were surging once again on Wednesday as Wall Street grows ever-more bullish on the prospects of legalization and U.S. imports.
HENDERSON, NV / ACCESSWIRE / September 19, 2018 / It's just a matter of time before medical marijuana will become legal in all 50 states. It's not surprising when you consider a recent poll shows 93% of ...
Morgan Stanley expects the DEA to drop Epidiolex from Schedule I — the same level as cocaine, heroin and other illegal substances — to Schedule IV, where Xanax, Ambien and Tramadol rank. At worst, it would fall to Schedule III alongside moderately to lowly addictive drugs like codeine and anabolic steroids, Lebowitz said.
NEW YORK, NY / ACCESSWIRE / September 19, 2018 / U.S. markets closed up Tuesday on the strength of upbeat corporate earnings and strong economic data. On Tuesday, China announced tariffs of between 5 to ...
Tilray CEO Brendan Kennedy told CNBC that pharmaceutical companies must start thinking about partnering with cannabis producers as a "hedge" against the space.
SAN DIEGO (AP) — In a rare move, the U.S. government has approved the importation of marijuana extracts from Canada for a clinical trial, highlighting a new avenue for American researchers who have long had trouble obtaining the drug for medical studies.
Cannabis stocks are soaring this week. Yahoo Finance's Seana Smith, Dion Rabouin, and Maylan Studart talk with Cassandra Farrington, CEO of Marijuana Business Daily about which areas of this fast growing sector are here to stay.